$230.28
0.43% today
NYSE, Feb 28, 04:45 pm CET
ISIN
US7611521078
Symbol
RMD

ResMed Stock price

$231.28
-23.42 9.20% 1M
-10.97 4.53% 6M
+2.59 1.13% YTD
+50.29 27.79% 1Y
-15.47 6.27% 3Y
+68.56 42.13% 5Y
+166.92 259.35% 10Y
NYSE, Closing price Thu, Feb 27 2025
-3.33 1.42%
ISIN
US7611521078
Symbol
RMD
Sector

Key metrics

Market capitalization $33.97b
Enterprise Value $34.29b
P/E (TTM) P/E ratio 27.32
EV/FCF (TTM) EV/FCF 24.63
EV/Sales (TTM) EV/Sales 6.96
P/S ratio (TTM) P/S ratio 6.89
P/B ratio (TTM) P/B ratio 6.47
Dividend yield 0.83%
Last dividend (FY24) $1.92
Revenue growth (TTM) Revenue growth 9.38%
Revenue (TTM) Revenue $4.93b
EBIT (operating result TTM) EBIT $1.56b
Free Cash Flow (TTM) Free Cash Flow $1.39b
Cash position $521.94m
EPS (TTM) EPS $8.46
P/E forward 25.28
P/S forward 6.64
EV/Sales forward 6.70
Short interest 6.50%
Show more

Is ResMed a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

ResMed Stock Analysis

Unlock Scores for Free

Analyst Opinions

28 Analysts have issued a ResMed forecast:

18x Buy
64%
9x Hold
32%
1x Sell
4%

Analyst Opinions

28 Analysts have issued a ResMed forecast:

Buy
64%
Hold
32%
Sell
4%

Financial data from ResMed

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
4,927 4,927
9% 9%
100%
- Direct Costs 2,095 2,095
1% 1%
43%
2,832 2,832
16% 16%
57%
- Selling and Administrative Expenses 734 734
5% 5%
15%
- Research and Development Expense 319 319
5% 5%
6%
1,779 1,779
24% 24%
36%
- Depreciation and Amortization 219 219
2% 2%
4%
EBIT (Operating Income) EBIT 1,560 1,560
28% 28%
32%
Net Profit 1,249 1,249
40% 40%
25%

In millions USD.

Don't miss a Thing! We will send you all news about ResMed directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ResMed Stock News

Neutral
GlobeNewsWire
2 days ago
New insights from 30,026 people across 13 markets show the global scale of poor sleep and its impact on health, work, and relationships New insights from 30,026 people across 13 markets show the global scale of poor sleep and its impact on health, work, and relationships
Neutral
GlobeNewsWire
17 days ago
Jan De Witte joins GHO Capital as Operating Partner Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP (“GHO”), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operati...
Positive
Seeking Alpha
18 days ago
ResMed reported $1.28 billion in revenue and $2.43 EPS, driven by strong demand for AirSense 11 and effective cost management. Rising awareness of sleep apnea, aided by wearable devices like Apple Watch, underscores a significant growth opportunity, with millions still undiagnosed and untreated globally. Concerns over GLP-1 drugs reducing CPAP demand have diminished.
More ResMed News

Company Profile

ResMed, Inc. engages in the development, manufacturing, distribution, and marketing of medical equipment and software solutions. The company operates through the following segments: Sleep and Respiratory Care, and SaaS. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The SaaS segment engages in the supply of business management software as a service to out-of-hospital health providers. Its product portfolio includes devices, diagnostic products, mask systems, headgear and other accessories, and dental devices. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Head office United States
CEO Mick Farrell
Employees 9,980
Founded 1989
Website www.resmed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today